Indivior Pharmaceuticals (INDV) Change in Accured Expenses (2024 - 2026)

Indivior Pharmaceuticals' Change in Accured Expenses history runs 3 years deep, the most recent figure standing at -$86.0 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 206.17% year-over-year to -$86.0 million in Q1 2026; TTM through Mar 2026 was -$126.0 million, a 241.57% decrease from a year earlier, with the FY2025 full-year figure at $41.0 million, up 412.5% from the prior year.
• Change in Accured Expenses slipped to -$86.0 million in Q1 2026 per INDV's latest filing, from -$8.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $81.0 million in Q1 2025 and bottomed at -$86.0 million in Q1 2026.
• The 3-year median for Change in Accured Expenses is $1.0 million (2024), against an average of -$4.6 million.
• Biggest YoY gain for Change in Accured Expenses was 87.3% in 2025; the steepest drop was 920.0% in 2025.
• Year by year, Change in Accured Expenses stood at -$63.0 million in 2024, then jumped by 87.3% to -$8.0 million in 2025, then plunged by 975.0% to -$86.0 million in 2026.
• Per Business Quant, the three latest INDV Change in Accured Expenses figures stand at -$86.0 million (Q1 2026), -$8.0 million (Q4 2025), and -$82.0 million (Q3 2025).